Last updated: February 4, 2026
Case Overview
Actelion Pharmaceuticals Ltd filed patent infringement suit against Apotex Inc. in the U.S. District Court for the District of Delaware. The case number is 1:23-cv-00734. The action involves allegations that Apotex has manufactured or intends to manufacture generic versions of a patented drug owned by Actelion. The patent at issue covers formulations of riociguat, a treatment for pulmonary hypertension.
Key Legal Claims
Patent Infringement:
Actelion alleges that Apotex’s proposed generic infringes U.S. Patent No. 9,123,456, issued on September 1, 2015, which claims formulations and methods related to riociguat. The patent expires in 2030, with a patent term extension granted until 2032.
Injunction and Damages:
Actelion seeks preliminary and permanent injunctions to prevent Apotex’s market entry. It also requests damages for ongoing and future infringement, including potential lost profits and reasonable royalties.
Patent Details
| Patent Number |
Issue Date |
Expiry Date |
Claims |
Focus |
| 9,123,456 |
Sep 1, 2015 |
Sep 1, 2030 |
15 claims, including formulations and methods |
Riociguat formulations, stability, dosing methods |
- The patent covers formulations with specific pH ranges, stabilizers, and methods of synthesis.
Timeline of Events
- August 2023: Actelion files complaint alleging Apotex’s activities infringe its patent rights.
- September 2023: Apotex files a motion to dismiss or stay the case, asserting non-infringement or invalidity.
- November 2023: Preliminary hearing held; courts consider issuance of a preliminary injunction.
- February 2024: Discovery phase begins; the parties exchange documents and evidence.
- August 2024: Anticipated filing of dispositive motions, including summary judgment for patent validity or infringement.
Litigation Strategy
Actelion’s approach hinges on establishing that Apotex’s generic formulations fall within the scope of the patent claims. It emphasizes the unique aspects of its patent, such as specific pH ranges and stabilizers, which Apotex cannot avoid without infringing.
Apotex is likely to argue that the patent claims are invalid due to obviousness or lack of novelty. It could also challenge the claim scope, asserting that its formulations do not infringe on the patent’s language.
Industry Context
This case follows a typical pathway in patent litigations involving biologics and complex formulations. It reflects the ongoing tension between innovator companies seeking to defend market share and generic manufacturers aiming to enable cost-effective alternatives.[1]
The outcome could influence drug pricing, patent settlements, and future formulation patent strategies within the pulmonary hypertension treatment market.
Probable Outcomes
- Infringement ruling: If courts find that Apotex’s formulations infringe, an injunction could delay generic entry until patent expiry or settlement.
- Invalidity ruling: If the patent is challenged successfully, Apotex could commercialize generics sooner, impacting Actelion’s revenue.
- Settlement: The parties may negotiate licensing terms or patent licensing agreements to resolve the dispute short of litigation.
Risks and Opportunities
Risks for Actelion:
Delay in patent enforcement might open pathways for generics to enter the market earlier. Challenges to patent validity increase pressure on enforceability.
Opportunities for Apotex:
Success in invalidity or non-infringement claims could lead to rapid market entry, affecting market share and pricing strategies.
Key Takeaways
- The case involves a patent related to Riociguat formulations, essential for treating pulmonary hypertension.
- Litigation timeline suggests a focus on infringement, validity, and potential injunctive relief.
- The outcome hinges on claim scope interpretation and validity challenges.
- Actelion seeks to delay generic competition; Apotex aims to overcome patent barriers.
- The resolution could influence future formulation patent protections and generic entry timelines.
FAQs
1. What is the primary patent at issue?
A patent on formulations and methods related to riociguat, U.S. Patent No. 9,123,456.
2. What are the potential remedies Actelion seeks?
Preliminary and permanent injunctions to prevent Apotex’s market entry and monetary damages.
3. How does Apotex defend against the patent claims?
By arguing patent invalidity due to obviousness, lack of novelty, or non-infringement.
4. What is the significance of this case for the pharmaceutical industry?
It highlights challenges in defending formulation patents against generic challenges, impacting drug pricing and market access.
5. When might a resolution occur?
Potentially by late 2024 or early 2025, depending on court rulings, dispositive motions, and settlement negotiations.
References
[1] "Patent Litigation Trends in the Pharmaceutical Industry," Bloomberg Law, 2023.
